Clinical Trial

An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 1, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, prospective, exploratory clinical study, which is divided into two phases: dose escalation phase (Phase Ia) and expansion phase (Phase Ib). After completing the dose-escalation phase (Stage Ia) (5-11 patients), the investigator will select the dose group (RP2D) based on safety, tolerability, and preliminary immune-related characteristics and efficacy data, and choose 2-3 advanced solid tumors to enter the expansion phase (Stage Ib).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-04; most recent amendment 2025-04-29.
Status change: Not Yet Recruiting → Recruiting 2024-07-31
Trial Details
NCT Number NCT06497010
Lead Sponsor The Affiliated Hospital Of Guizhou Medical University
Collaborators: Innovac Therapeutics
Conditions Advanced Solid Tumor
Enrollment 40 participants
Start Date 2024-08-29
Primary Completion 2026-07 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-01